Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Fund Manager results
Tips from these results
Recent Share tips:
- Buy Legal & General Group (LGEN) by Christopher Ruane in The Motley Fool
- Buy Domino's Pizza Group (DOM) by Lucy Tobin in The Times - Tempus
- Buy Unilever (ULVR) by Charlie Keough in The Motley Fool
- Hold Elementis (ELM) by Tom Winnifrith in ShareProphets
- Sell Lifesafe Holdings (LIFS) by Steve Moore in ShareProphets
- Overweight Spectris (SXS) by Barclays
- Overweight Workspace Group (WKP) by Barclays
- Buy InterContinental Hotels Group (IHG) by Ben McPoland in The Motley Fool
- Avoid Kitwave Group (KITW) by Steve Moore in ShareProphets
- Buy Hiscox Limited (DI) (HSX) by Goldman Sachs
- Buy Rotork (ROR) by Jefferies
- Hold Telecom Plus (TEP) by Tom Winnifrith in ShareProphets
- Strong Buy OptiBiotix Health (OPTI) by Hot Stock Rockets in ShareProphets
- Avoid Surface Transforms (SCE) by Steve Moore in ShareProphets
- Buy InterContinental Hotels Group (IHG) by Bank of America
- Hold GSK (GSK) by DZ Bank
- Neutral Intertek Group (ITRK) by Goldman Sachs
- Neutral InterContinental Hotels Group (IHG) by Goldman Sachs
- Overweight Tesco (TSCO) by Barclays
- Sector Perform SIG (SHI) by RBC Capital
Verici DX (VRCI) Share Price
Health Care Sector
NOTE: This is based on 9 open tips for Verici DX (VRCI)
| Latest Bid : 7.00p | Latest Ask : 7.50p |
| High Today : 7.50p | Low Today : 7.00p |
| This Years High : 17.50p | This Years Low : 5.75p |
| Volume : 146,957 | MKT Cap : £17.55M |
| Trading Velocity : Premium Only | Activity Score : Premium Only |
| Consensus Score : Premium Only | Momentum Score : Premium Only |
Verici DX (VRCI) Overview
Verici was incorporated in April 2020 as a wholly-owned subsidiary of Renalytix AI plc ("RENX"), the AIM-quoted developer of artificial intelligence decision support and clinical management tools for improving early diagnosis, continual monitoring and drug development for kidney disease. The Company develops tests to understand how a patient is likely and may be responding to kidney transplant.Verici DX (VRCI) Latest Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Avoid | Steve Moore | Premium Only | 2024-02-14 16:05:00 14/02/2024 | 14.71% |
| Avoid | Steve Moore | Premium Only | 2023-11-15 14:35:00 15/11/2023 | 19.44% |
| Avoid | Steve Moore | Premium Only | 2023-07-20 16:25:00 20/07/2023 | 36.96% |
| Watch | Steve Moore | Premium Only | 2023-07-03 11:40:00 03/07/2023 | – |
| Avoid | Steve Moore | Premium Only | 2023-06-05 14:35:00 05/06/2023 | 34.09% |
Verici DX (VRCI) Active Short Positions
| Fund Manager | Position | Date | ||
|---|---|---|---|---|
| No active short positions | ||||
| Latest Bid : 7.00p | Latest Ask : 7.50p |
| High Today : 7.50p | Low Today : 7.00p |
| This Years High : 17.50p | This Years Low : 5.75p |
| Volume : 146,957 | MKT Cap : £17.55M |
Verici DX Overview
Verici was incorporated in April 2020 as a wholly-owned subsidiary of Renalytix AI plc ("RENX"), the AIM-quoted developer of artificial intelligence decision support and clinical management tools for improving early diagnosis, continual monitoring and drug development for kidney disease. The Company develops tests to understand how a patient is likely and may be responding to kidney transplant.NOTE: This description is in part generated by ChatGPT and not an endorsement by or the opinion of Stockomendation Ltd.
Latest Verici DX Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| Avoid | Steve Moore | Premium Only | 2024-02-14 16:05:00 14/02/2024 | 14.71% |
| Avoid | Steve Moore | Premium Only | 2023-11-15 14:35:00 15/11/2023 | 19.44% |
| Avoid | Steve Moore | Premium Only | 2023-07-20 16:25:00 20/07/2023 | 36.96% |
| Watch | Steve Moore | Premium Only | 2023-07-03 11:40:00 03/07/2023 | – |
| Avoid | Steve Moore | Premium Only | 2023-06-05 14:35:00 05/06/2023 | 34.09% |